Cannabis Report
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, GoldenMind
Search This Board: 
Last Post: 8/18/2018 9:18:00 PM - Followers: 793 - Board type: Free - Posts Today: 0


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks

SUNRISE, Fla.Jan. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement.  Details of the procedure and the results are featured in the January issue of Men's Healthon newsstands now. Link here!!! ----->>>>

Ben Greenfield posted (Jan 16th, 2018) video at US Stem Cell clinic in Florida

Expecting Ben Greenfield's article to be found here once written any day now...

Press Releases:

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 08/08/2018 04:09:15 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 05/18/2018 04:05:16 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 05/18/2018 04:02:40 PM
USRM News: Quarterly Report (10-q) 05/09/2018 05:14:57 PM
USRM News: Small Company Offering and Sale of Securities Without Registration (d) 05/04/2018 04:37:37 PM
PlusOneCoin Top Posts
#97236   10-Q: SEC SUBPOENA TO Tomas and Comella AS INDIVIDUALS.... Hornet Driver 08/08/18 04:49:26 PM
#97274   Stem Cell Center Clinics = GONE..ANOTHER Tomas SCAM... Hornet Driver 08/08/18 11:46:13 PM
#96644   NEW PODCAST! We got to meet up with KRex0969 07/23/18 10:31:52 AM
#94862  Sticky Note Is this how USRM says the FDA / Gobsmacked01 05/16/18 09:43:09 PM
#85293  Sticky Note $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 GoldenMind 12/04/17 04:27:33 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#97597   I have a quetion DISBELIE1 : power11 08/18/18 09:18:00 PM
#97596   They won’t prevail. Look at previous cases Disbelief1 08/18/18 08:42:53 PM
#97595   USRM shall prevail and SOAR! yogi17 08/18/18 01:51:08 PM
#97594   YOU'RE SPOT ON Bayflynn, people DO NOT understand power11 08/18/18 12:33:50 PM
#97593   Yes, Now USRM have multiple locations.. Bayflynn 08/18/18 12:02:47 PM
#97592   The real reason USRM is being targeted Bayflynn 08/18/18 11:35:41 AM
#97591   WOW FDA Says Stem Cells "THERAPY OF THE Bayflynn 08/18/18 11:29:56 AM
#97590   Whigs, they’ve been taking this salary and also Ryguy008 08/18/18 10:01:36 AM
#97589   Do we really think we going up? rocketRider 08/18/18 12:28:46 AM
#97588   How can USRM put out a deceptive PR Top Penny 08/17/18 11:03:33 PM
#97587   NEXT WEEK WE ROCK! Lonewolf1 08/17/18 03:22:19 PM
#97586   YEP, USRM HAS FOUND A BOTTOM HERE. power11 08/17/18 03:14:05 PM
#97585   USRM BOTTOMED OUT. HEADED NORTH yogi17 08/17/18 02:23:11 PM
#97584   I think that's probably my bigger concern for TheWhigs 08/17/18 10:55:02 AM
#97583   Great 10q showing increased revenue for the 8th als money 08/17/18 10:29:24 AM
#97582   10-Q DISASTER: ON TRACK FOR RECORD LOSSES 2018 Hornet Driver 08/17/18 09:30:47 AM
#97581   I wish the Insurance Co. would cover Stem boardbrain1 08/17/18 09:04:25 AM
#97580   USRM Strong!!! $$IsEverything$$83 08/17/18 08:41:47 AM
#97579   40% growth in services rev QoQ. I see GoldenMind 08/17/18 08:17:22 AM
#97578   And what clinic do you think is opening???? Disbelief1 08/17/18 04:22:33 AM
#97576   NOW THAT THE NEW CLINIC IS OPEN AND power11 08/17/18 12:47:42 AM
#97575   That malpractice insurance Is pretty much your guys Ryguy008 08/16/18 10:05:54 PM
#97573   UNITED STATES vs Comella/USRM...LAWSUIT FILED..SCATHING... Hornet Driver 08/16/18 08:30:42 PM
#97572   Your Information is misleading Bayflynn 08/16/18 08:11:03 PM
#97571   NEW ATTORNEY BLOG: PRISON real possibility Comella/Tomas... Hornet Driver 08/16/18 08:06:35 PM
#97570   Nobody is going to jail Bayflynn 08/16/18 07:45:49 PM
#97569   WOW More FDA Approved STEM CELL STUDYS Bayflynn 08/16/18 07:40:54 PM
#97568   Please Do Not Over Exaggerate Bayflynn 08/16/18 07:39:11 PM
#97567   CDC: Drug overdoses hit new record 72,000 KRex0969 08/16/18 07:25:07 PM
#97565   Lol. You understand Kristi butchered this four Disbelief1 08/16/18 06:32:31 PM
#97564   I have 20/20 vision and my eyes are GetRichorGetHighTryn 08/16/18 05:18:38 PM
#97562   TIME WILL TELL I GUESS. power11 08/16/18 01:55:41 PM
#97561   I think buying has dried up. Disbelief1 08/16/18 01:18:11 PM
#97560   Yep Mtn1 08/16/18 12:39:52 PM
#97557   PATIENCE, PATIENCE, NO RUSH . GOT 2.2 MILLION power11 08/16/18 12:37:34 PM
#97556   Slap it !!!! Your not getting my 3.3 Moke31 08/16/18 12:30:58 PM
#97554   SELLING PRESSURE HAS SIMPLY DRIED UP. power11 08/16/18 11:59:31 AM
#97551   I AM WITH YOU lonewolf !! power11 08/16/18 11:32:20 AM
#97543   USRM LONG AND STRONG! Lonewolf1 08/16/18 10:02:58 AM
#97540   CBS TV FL, SCATHING REPORT ON COMELLA/USRM..holy cow.... Hornet Driver 08/16/18 09:05:18 AM
#97539   MARCH 1st, 2018..USRM IS UNDER SEC INVESTIGATION.... Hornet Driver 08/16/18 08:52:56 AM
#97536   Lol. NO, you’re wrong!!! It’s been based on Disbelief1 08/16/18 12:56:11 AM
#97534   EVERY GREAT ADVANCE IN THE MEDICAL FIELD STARTED power11 08/16/18 12:29:39 AM
#97533   UNITED STATES DOJ VS USRM INJUNCTION WORD FOR WORD.... Hornet Driver 08/16/18 12:21:06 AM
#97529   This isn’t JUST about the malpractice this is Disbelief1 08/15/18 11:36:16 PM
#97527   Maybe Dis, Bayflynn 08/15/18 11:26:48 PM
#97525   Ithis only means USRM could gain approval if Disbelief1 08/15/18 11:20:39 PM
#97524   Careful People Bayflynn 08/15/18 11:18:51 PM
#97523   First of all, USRM has not treated 100s Disbelief1 08/15/18 11:15:34 PM